Safety and Efficacy of Emixustat in Stargardt Disease
| Status: | Recruiting |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 16 - Any |
| Updated: | 12/13/2018 |
| Start Date: | November 7, 2018 |
| End Date: | March 2022 |
| Contact: | Clinical Trials Helpdesk |
| Email: | ClinicalTrials@acucela.com |
| Phone: | (206) 805 8310 |
A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride With Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease
The purpose of this study is to determine if emixustat hydrochloride reduces the rate of
progression of macular atrophy compared to placebo in subjects with Stargardt disease.
progression of macular atrophy compared to placebo in subjects with Stargardt disease.
Inclusion Criteria:
- A clinical diagnosis of macular atrophy secondary to Stargardt disease (STGD)
- Macular atrophy measured to fall within a defined size range
- Two mutations of the ABCA4 gene. If only one mutation, a typical STGD appearance of
the retina.
- Visual acuity in the study eye of at least 20/320
Exclusion Criteria:
- Macular atrophy secondary to a disease other than STGD
- Mutations of genes, other than ABCA4, that are associated with retinal degeneration
- Surgery in the study eye in the past 3 months
- Prior participation in a gene therapy or stem cell clinical trial for STGD
- Recent participation in a clinical trial for STGD evaluating a complement inhibitor or
vitamin A derivative
- Use of certain medications in the past 4 weeks that might interfere with emixustat
- An abnormal electrocardiogram (ECG)
- Certain abnormalities on laboratory blood testing
- Female subjects who are pregnant or nursing
We found this trial at
1
site
Click here to add this to my saved trials
